SecBot SecBot
SECBOTREPLAY Home › Report › ELAN

ELAN · Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs

Elanco Animal Health Inc · 8-K filed Aug 5, 2026 at 06:27 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 5, 2026 at 06:27 ET

Elanco reported Q2 2026 adjusted EPS of $0.34, a 26.5% beat vs. the $0.27 consensus, on revenue of $1.368B (8% organic constant currency growth). The company raised full-year guidance across all key metrics, revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, and adjusted EPS to $1.10-$1.16, while improving its year-end net leverage target to ~3.0x. This marks a second consecutive beat-and-raise quarter, driven by accelerating innovation product adoption (Zenrelia, Credelio Quattro) and faster-than-expected margin expansion from the Elanco Ascend productivity program.

  • Q2 2026 revenue of $1,368M, +10% reported YoY, +8% organic constant currency
  • Adjusted EPS of $0.34 beat consensus of $0.27 by 26.5%
  • Full-year 2026 guidance raised: revenue to $5.09B-$5.14B, adjusted EBITDA to $1.01B-$1.035B, adjusted EPS to $1.10-$1.16
  • Net leverage ratio improved to 3.1x at quarter-end, down from 3.5x at Q1 end and 3.6x at Dec 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access